Free Writing Prospectus
Issuer Free Writing Prospectus   

Filed Pursuant to Rule 433

Registration No. 333-172617

May 10, 2012

Amgen Inc.


Dated May 10, 2012

$1,250,000,000 2.125% Senior Notes due 2017

This term sheet relates only to the securities described below and supplements and should be read together with the preliminary prospectus supplement, dated May 10, 2012 and the accompanying prospectus (including the documents incorporated by reference in the accompanying prospectus) relating to these securities.



   Amgen Inc.


   Senior Unsecured

Principal Amount:


Maturity Date:

   May 15, 2017



Price to Public:

   99.821%, plus accrued interest from May 15, 2012 if settlement occurs after such date

Yield to Maturity:


Treasury Benchmark:

   0.875% due April 30, 2017

Spread to Benchmark:

   140 bps

Interest Payment Dates:

   May 15 and November 15, commencing November 15, 2012

Reinvestment Rate:

   0.20% plus the arithmetic mean of the yields under the respective heading “Week Ending” published in the most recent Statistical Release under the caption “Treasury Constant Maturities” for the maturity (rounded to the nearest month) corresponding to the remaining life to maturity, as of the payment date of the principal being redeemed or paid.

Net Proceeds to Issuer (before expenses):


Trade Date:

   May 10, 2012

Settlement Date:

   May 15, 2012 (T+3)






   $2,000 x $1,000



Moody’s: Baa1

S&P: A+

Fitch: BBB


   Joint Book-Running Managers:
   Goldman, Sachs & Co.
   J.P. Morgan Securities LLC
   Merrill Lynch, Pierce, Fenner & Smith


   Morgan Stanley & Co. LLC
   UBS Securities LLC


Senior Co-Managers:


Barclays Capital Inc.


Citigroup Global Markets Inc.


Credit Suisse Securities (USA) Inc.


Deutsche Bank Securities Inc.


Mitsubishi UFJ Securities (USA), Inc.




HSBC Securities (USA) Inc.


SMBC Nikko Capital Markets Limited


Wells Fargo Securities, LLC

Amgen Inc. has filed a registration statement (including a prospectus dated as of March 4, 2011) and a prospectus supplement dated as of May 10, 2012 with the SEC for the offering to which this communication relates. Before you invest, you should read the prospectus in that registration statement, the prospectus supplement and other documents Amgen Inc. has filed with the SEC for more complete information about the issuer and this offering. You should rely on the prospectus, prospectus supplement and any relevant free writing prospectus or term sheet for complete details. You may get these documents for free by visiting the SEC web site at Alternatively, copies of the prospectus and the prospectus supplement may be obtained from Goldman, Sachs & Co. by calling 866-471-2526, J.P. Morgan Securities LLC by calling 212-834-4533 (collect), Merrill Lynch, Pierce, Fenner & Smith Incorporated by calling 800-294-1322 or Morgan Stanley & Co. LLC by calling 866-718-1649.

The security ratings above are not a recommendation to buy, sell or hold the securities offered hereby. The ratings may be subject to revision or withdrawal at any time by Moody’s, S&P and Fitch. Each of the security ratings above should be evaluated independently of any other security rating.